Treatment of Metastatic Colorectal Cancer in the Elderly
Metastatic colorectal cancer (CRC) is the second leading cause of cancer related mortality in the United States. The median age of patients at diagnosis is over 70, so as the American population ages, it can be expected that the incidence of CRC will also increase. There is limited prospective data regarding the safety and efficacy of chemotherapy in elderly patients with metastatic CRC. However, the data that are available suggest that elderly patients with a good performance status have a similar likelihood of response to currently available chemotherapy, though perhaps a somewhat higher likelihood of toxicities such as myelosuppression. This paper reviews the available data and recommendations for the treatment of this patient population.
Unable to display preview. Download preview PDF.
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 1.SEER Cancer Statistics Review, 1975–2006, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2006/, based on November 2008 SEER data submission, posted to the SEER web site, 2009
- 2.Jemal, A.: CA: A Cancer Journal for Clinicians, May 27, 2009; advance online edition. News release, American Cancer Society. American Cancer Society: Cancer Prevention & Early Detection Facts & Figures, 2009Google Scholar
- 3.Lichtman, S, et al.: Colorectal Cancer in the Elderly Patient: Assessment and Treatment. New York, NY: Oncology Publishing Group, 2005Google Scholar
- 23.Hurwitz H, Fehrenbacher L, Novotny W, et al.: Bevacizumab plus irinotean, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350(23):2335–2342Google Scholar
- 27.Raman AK, et al.: Bevacizumab related adverse events among various age groups of elderly patients with advanced colorectal cancer. J Clin Oncol 2007, 25(18S):14546.Google Scholar
- 29.Lichtman, S., et al.: Chemotherapy Toxicity: Focus on the Older Cancer Patient. New York, NY: Oncology Publishing Group, 2008Google Scholar
- 30.Pasetto LM, et al.: How many colorectal cancer (CRC) patients older than 70 years may be safely treated with bevacizumab? J Clin Oncol 2006, 24:13589.Google Scholar
- 34.Thomas M: Cetuximab: adverse event profile and recommendations for toxicity management. Clin J Oncol Nursing 2005, 9(3):1092–1095.Google Scholar